Trial Profile
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Latin America
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2020
Price :
$35
*
At a glance
- Drugs CYD TDV (Primary)
- Indications Dengue
- Focus Pharmacodynamics
- Sponsors Sanofi Pasteur
- 01 Oct 2020 Results of this follow-up study evaluating immune response persistence and safety of CYD-TDV booster dose up to month 24 post-booster published in the Pediatric Infectious Disease Journal
- 24 May 2019 Status changed from active, no longer recruiting to completed.
- 01 May 2019 Results published in the Pediatric Infectious Disease Journal